Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010–2015
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010–2015
Authors
Keywords
-
Journal
Expert Review of Neurotherapeutics
Volume 16, Issue 6, Pages 689-700
Publisher
Informa UK Limited
Online
2016-04-09
DOI
10.1080/14737175.2016.1176531
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel Agents for Relapsing Forms of Multiple Sclerosis
- (2016) Rebecca Straus Farber et al. Annual Review of Medicine
- Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease
- (2016) Steven J. Greenberg et al. Therapeutic Advances in Neurological Disorders
- Unraveling the Hygiene Hypothesis of helminthes and autoimmunity: origins, pathophysiology, and clinical applications
- (2015) Mathilde Versini et al. BMC Medicine
- Disposition of Flavonoids Impacts their Efficacy and Safety
- (2015) Yong Ma et al. CURRENT DRUG METABOLISM
- ATON: Results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis
- (2015) Robert C. Sergott et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies
- (2015) Jesus Lovera et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect
- (2015) A Voldsgaard et al. Multiple Sclerosis Journal
- Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect
- (2015) A Voldsgaard et al. Multiple Sclerosis Journal
- The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease
- (2014) Helena Marco et al. BMC MUSCULOSKELETAL DISORDERS
- Regulatory T cells in autoimmune neuroinflammation
- (2014) Markus Kleinewietfeld et al. IMMUNOLOGICAL REVIEWS
- Therapeutic uses of anti- 4-integrin (anti-VLA-4) antibodies in multiple sclerosis
- (2014) N. Schwab et al. INTERNATIONAL IMMUNOLOGY
- A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
- (2014) T. L. Vollmer et al. JOURNAL OF NEUROLOGY
- Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial
- (2014) Ludwig Kappos et al. LANCET NEUROLOGY
- Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial
- (2014) Thomas P Leist et al. LANCET NEUROLOGY
- Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study
- (2014) P. S. Sorensen et al. NEUROLOGY
- 2 1 Integrin Regulates Th17 Cell Activity and Its Neutralization Decreases the Severity of Collagen-Induced Arthritis
- (2013) M.-A. El Azreq et al. JOURNAL OF IMMUNOLOGY
- Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients
- (2013) L. Michel et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Association of serum bilirubin and uric acid levels changes during neuroinflammation in patients with initial and relapsed demyelination attacks
- (2013) Srdjan Ljubisavljevic et al. METABOLIC BRAIN DISEASE
- Trichuris suis ova in relapsing-remitting multiple sclerosis and clinically isolated syndrome (TRIOMS): study protocol for a randomized controlled trial
- (2013) Berit Rosche et al. Trials
- Polyunsaturated fatty acids in multiple sclerosis therapy
- (2012) S. Wergeland et al. ACTA NEUROLOGICA SCANDINAVICA
- ω-3 Fatty Acid Treatment in Multiple Sclerosis (OFAMS Study)
- (2012) Øivind Torkildsen et al. ARCHIVES OF NEUROLOGY
- Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor-Negative Breast Cancer
- (2012) K. D. Crew et al. Cancer Prevention Research
- Urate in Parkinson’s Disease: More Than a Biomarker?
- (2012) Xiqun Chen et al. Current Neurology and Neuroscience Reports
- Progressive multiple sclerosis: pathology and pathogenesis
- (2012) Hans Lassmann et al. Nature Reviews Neurology
- Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
- (2012) Giancarlo Comi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Deficiency in TNFRSF13B (TACI) expands T-follicular helper and germinal center B cells via increased ICOS-ligand expression but impairs plasma cell survival
- (2012) X. Ou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Toxicity and Pathology of Selected Dietary Herbal Medicines
- (2012) June K. Dunnick et al. TOXICOLOGIC PATHOLOGY
- Epigallocatechin-3-Gallate Ameliorates Experimental Autoimmune Encephalomyelitis by Altering Balance among CD4+ T-Cell Subsets
- (2011) Junpeng Wang et al. AMERICAN JOURNAL OF PATHOLOGY
- A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
- (2011) A. Cuker et al. BLOOD
- Cladribine
- (2011) Thomas P. Leist et al. CLINICAL NEUROPHARMACOLOGY
- How do immune cells overcome the blood-brain barrier in multiple sclerosis?
- (2011) Catherine Larochelle et al. FEBS LETTERS
- Progressive multifocal leukoencephalopathy and natalizumab
- (2011) Kerstin Hellwig et al. JOURNAL OF NEUROLOGY
- Insight into the mechanism of laquinimod action
- (2011) W. Brück et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
- (2011) Ludwig Kappos et al. LANCET
- Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial
- (2011) Per Soelberg Sorensen et al. LANCET NEUROLOGY
- Probiotic helminth administration in relapsing–remitting multiple sclerosis: a phase 1 study
- (2011) JO Fleming et al. Multiple Sclerosis Journal
- Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study
- (2011) S Cook et al. Multiple Sclerosis Journal
- Neuroprotective Effect of Combination Therapy of Glatiramer Acetate and Epigallocatechin-3-Gallate in Neuroinflammation
- (2011) Katja Herges et al. PLoS One
- Therapeutic Approaches to Multiple Sclerosis
- (2010) Sven G. Meuth et al. BIODRUGS
- Therapeutic Approaches to Multiple Sclerosis
- (2010) Jochen C. Ulzheimer et al. BIODRUGS
- Alpha2beta1 integrin is the major collagen-binding integrin expressed on human Th17 cells
- (2010) Marc Boisvert et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4+ T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein
- (2010) Christopher T. Harp et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Cutting Edge: Novel Function of B Cell-Activating Factor in the Induction of IL-10-Producing Regulatory B Cells
- (2010) M. Yang et al. JOURNAL OF IMMUNOLOGY
- Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon β in relapsing- remitting Multiple Sclerosis (ASIIMS) trial
- (2010) Richard E Gonsette et al. Multiple Sclerosis Journal
- Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: Outcomes in 102 patients
- (2010) Michael K. Hehir et al. MUSCLE & NERVE
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
- (2010) Gavin Giovannoni et al. NEW ENGLAND JOURNAL OF MEDICINE
- A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing—remitting multiple sclerosis (TIME MS)
- (2010) Gina M. Remington et al. Therapeutic Advances in Neurological Disorders
- A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis
- (2010) Elliot M. Frohman et al. Therapeutic Advances in Neurological Disorders
- Treatment of Neuromyelitis Optica With Mycophenolate Mofetil
- (2009) Anu Jacob et al. ARCHIVES OF NEUROLOGY
- Green tea EGCG suppresses T cell proliferation through impairment of IL-2/IL-2 receptor signaling
- (2009) Dayong Wu et al. FREE RADICAL BIOLOGY AND MEDICINE
- Exposure and toxicity of green tea polyphenols in fasted and non-fasted dogs
- (2009) I.M. Kapetanovic et al. TOXICOLOGY
- Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis
- (2009) Lahar R Mehta et al. Nature clinical practice. Neurology
- Interferon-β increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity
- (2008) M. Krumbholz et al. BRAIN
- TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties
- (2008) Fabienne Mackay et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Neurodegeneration in multiple sclerosis: The role of oxidative stress and excitotoxicity
- (2008) R.E. Gonsette JOURNAL OF THE NEUROLOGICAL SCIENCES
- Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
- (2008) G Comi et al. LANCET
- Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study
- (2008) Benjamin M Segal et al. LANCET NEUROLOGY
- Complementary and alternative medicine for multiple sclerosis
- (2008) S Schwarz et al. Multiple Sclerosis Journal
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started